SABS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SAB Biotherapeutics (SABS) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 ready to deploy. The chart is technically constructive, but the stock is still below the pivot level and recent news shows heavier losses plus a dilutive stock offering. With no AI Stock Picker or SwingMax buy signal and mixed near-term stock trend expectations, the better call is to wait rather than buy immediately.
The technical picture is mildly bullish but not decisive. MACD histogram is positive and expanding, RSI_6 at 54.34 is neutral, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), which supports an upward trend. However, the current price of 3.75 is below the pivot at 3.948 and below resistance at 4.385, so the stock has not yet confirmed a strong breakout. The recent pattern outlook also suggests limited near-term upside and some downside risk over the next month.
["H.C. Wainwright raised its price target to $10 and kept a Buy rating after the Q1 report.", "Rodman & Renshaw initiated coverage with a Buy rating and $13 target.", "Chardan raised its target to $14 and kept a Buy rating after additional Phase I SAB-142 data.", "SAFEGUARD Phase 2b trial timelines remain on track, with enrollment expected to complete in the second half of 2026.", "The company reported a strong cash position of $217.6 million after recent financing, which supports ongoing development."]
["Q1 2026 net loss widened sharply to $18.9 million from $5.2 million in Q1 2025.", "The company announced an $85 million stock offering, which can pressure the share price.", "Hedge funds are reported as selling aggressively over the last quarter.", "The stock is still below its pivot level, so the price has not yet confirmed a stronger breakout.", "The stock trend model suggests negative performance over the next month."]
Latest quarter: Q1 2026. Financials were weak on profitability, with a net loss of $18.9 million versus a $5.2 million loss in Q1 2025, showing losses have widened meaningfully year over year. On the positive side, the company says it has a cash position of $217.6 million after recent financing, which gives it runway for its clinical programs. The main growth story remains clinical progress rather than earnings growth.
Analyst sentiment is clearly bullish. Recent updates show multiple Buy ratings and rising price targets: H.C. Wainwright lifted its target to $10 from $7, Rodman & Renshaw initiated at Buy with a $13 target, and Chardan raised its target to $14 from $12. The Wall Street pros see upside tied to SAB-142 and the SAFEGUARD trial, but the pro case is still highly dependent on future clinical data, while the con case is dilution, losses, and execution risk. Congress/politician trading data shows no recent activity.
